- Home
- LCTX vs ASPS Comparison
LCTX vs ASPS Comparison
Compare LCTX & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- ASPS
- Stock Information
- Founded
- LCTX 1990
- ASPS 1999
- Country
- LCTX United States
- ASPS Luxembourg
- Employees
- LCTX N/A
- ASPS N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- ASPS Other Consumer Services
- Sector
- LCTX Health Care
- ASPS Consumer Discretionary
- Exchange
- LCTX Nasdaq
- ASPS Nasdaq
- Market Cap
- LCTX 107.3M
- ASPS 108.7M
- IPO Year
- LCTX N/A
- ASPS N/A
- Fundamental
- Price
- LCTX $1.03
- ASPS $13.30
- Analyst Decision
- LCTX Strong Buy
- ASPS
- Analyst Count
- LCTX 5
- ASPS 0
- Target Price
- LCTX $4.20
- ASPS N/A
- AVG Volume (30 Days)
- LCTX 4.1M
- ASPS 67.4K
- Earning Date
- LCTX 08-07-2025
- ASPS 07-24-2025
- Dividend Yield
- LCTX N/A
- ASPS N/A
- EPS Growth
- LCTX N/A
- ASPS N/A
- EPS
- LCTX N/A
- ASPS N/A
- Revenue
- LCTX $9,557,000.00
- ASPS $164,104,000.00
- Revenue This Year
- LCTX N/A
- ASPS $38.29
- Revenue Next Year
- LCTX $232.66
- ASPS N/A
- P/E Ratio
- LCTX N/A
- ASPS N/A
- Revenue Growth
- LCTX 19.42
- ASPS 13.12
- 52 Week Low
- LCTX $0.37
- ASPS $3.46
- 52 Week High
- LCTX $1.15
- ASPS $14.63
- Technical
- Relative Strength Index (RSI)
- LCTX 65.72
- ASPS 69.18
- Support Level
- LCTX $0.97
- ASPS $11.65
- Resistance Level
- LCTX $1.12
- ASPS $14.48
- Average True Range (ATR)
- LCTX 0.10
- ASPS 1.26
- MACD
- LCTX -0.00
- ASPS 0.31
- Stochastic Oscillator
- LCTX 81.48
- ASPS 78.53
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About ASPS Altisource Portfolio Solutions S.A.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.